

RCE 1002

REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of a utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).	Application Number	09/785,951
	Filing Date	February 16, 2001
	First Named Inventor	Michael J. Mullan
	Group Art Unit	1632
	Examiner Name	D. Crouch
	Attorney Docket Number	01097.0008U2

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE:

37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB.29) instead of a RCE. To be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Professional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

RECEIVED
SEP 17 2003
FBI CENTER 1600/2900

1. Submission required under 37 C.F.R. § 1.114

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on
Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on
- iii. ☐ Other _____
- b. ☒ Enclosed
- i. ☐ Amendment After Final Office Action
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other Terminal Disclaimer Under 37 C.F.R. § 1.321(c) _____

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37. C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months, Fee under 37 C.F.R. § 1.17(i) required)
- b. ☐ Other _____

3. Fees

- a. ☐ Check in the amount of \$ enclosed for the fees designated below.
- b. ☒ Payment by credit card in the amount of \$895.00 for the fees designated below. (Form PTO-2038 enclosed).
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.
- c. ☐ The Director is hereby authorized to charge the amount of \$**** for the fees designated below to Deposit Account No. 14-0629.
- d. ☒ Fees
- ☒ RCE fee required under 37 C.F.R. § 1.17(e) 01 FC:2801 375.00 OP
- ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
- ☐ Other Terminal Disclaimer fee under 37 C.F.R. § 1.20(d) _____
- e. ☐ The Director is hereby authorized to charge any underpayment or credit any overpayment to Deposit Account No. 14-0629.

09/17/2003 AMONDAF1 00000027 09785951

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Gwendolyn D. Spratt	Registration No. (Attorney/Agent)	36,016
Signature	<i>Gwendolyn D. Spratt</i>	Date	9-16-03

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Name of Person Mailing(Print/Type)	Gwendolyn D. Spratt		
Signature	<i>Gwendolyn D. Spratt</i>	Date	9-16-03



ATTORNEY DOCKET NO. 01097.0008U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
MULLAN)	Art Unit: 1632
)	
Application No. 09/785,951)	Examiner: Crouch, D.
)	
Filing Date: February 16, 2001)	Confirmation No. 7348
)	
For: "TEST AND MODEL FOR)	
ALZHEIMER'S DISEASE")	

AMENDMENT AFTER FINAL OFFICE ACTION

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer No. 23859

Sir:

This is responsive to the Office Action dated March 10, 2003 issued regarding the above-referenced patent application. Please amend the above-referenced application as follows.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.